▶ Full Post Text
Hello, if you don't know me, I post way more in the daily, but I like to write and like to post from time to time around just names that I find interesting. By no means is post saying you should buy these names, but I just find them really interesting and really under discussed.
My investment philosophy falls into the GARPy mindset. I think a big risk for a lot of modern investors is over paying for an asset. That's where the GARPy aspect really helps out, since I don't mind paying somewhat of a premium if the company is quality. Goes back to the Buffet idea of “It’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price.”
**STVN - Stevanato Group S.p.A.**
What they do:
>Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
>It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services.
Fundamentals
[https://finviz.com/quote.ashx?t=STVN&p=d](https://finviz.com/quote.ashx?t=STVN&p=d)
Right now this company is really a story around FCF and CAPEX. This company is based out of Italy. but is in the process of spending a lot of CAPEX to build a new production plant in Fishers, Indiana. I believe this should be opened soon since the company was investing so much in CAPEX, it was causing the FCF to be negative. Last quarter, it's going positive again. This is basically a bet on the company going after the higher margin business around single use injectables. There could be some added fear around GLP1s and the pill, since they do the syringe for the single injectables.
**WAY - Waystar Holding Corp.**
What they do:
>Waystar Holding Corp. develops a cloud-based software solution for healthcare payments.
>Its platform offers financial clearance, patient financial care, claim and payment management, denial prevention and recovery, revenue capture, and analytics and reporting solutions.
Fundamentals
[https://finviz.com/quote.ashx?t=WAY&p=d](https://finviz.com/quote.ashx?t=WAY&p=d)
Really really interesting company. Recently they just acquired a new software company, Iodine Software. The move was to try to expand the company into a new segment, admin waste. The company is pretty imbedded in hospitals for billing purposes. I want to say they process like 1/2 of all US patient claims. The company is trying to pivot more into AI and trying to automate the claims and waste part.
The bad about the company is really the IPO and Private Equity dumping shares. It's interesting, since PE is basically selling a bunch, it looks like the company is issues more shares, but in reality, the float is increasing. This isn't great, but overall, the company seems to have a solid moat and not terrible fundamentals. Just has the PE overhang.